Cargando…

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smit, Marjon A, Maddalo, Gianluca, Greig, Kylie, Raaijmakers, Linsey M, Possik, Patricia A, van Breukelen, Bas, Cappadona, Salvatore, Heck, Albert JR, Altelaar, AF Maarten, Peeper, Daniel S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300494/ https://www.ncbi.nlm.nih.gov/pubmed/25538140 http://dx.doi.org/10.15252/msb.20145450

Ejemplares similares

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

Identification of Protein Complexes by Integrating Protein Abundance and Interaction Features Using a Deep Learning Strategy
por: Li, Bohui, et al.
Publicado: (2023)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Protein acetylation affects acetate metabolism, motility and acid stress response in Escherichia coli
por: Castaño-Cerezo, Sara, et al.
Publicado: (2014)

Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths
por: Smit, Marjon A., et al.
Publicado: (2010)

Current challenges in software solutions for mass spectrometry-based quantitative proteomics
por: Cappadona, Salvatore, et al.
Publicado: (2012)

ROCK inhibitor enhances the growth and migration of BRAF‐mutant skin melanoma cells
por: Chang, Fei, et al.
Publicado: (2018)

Comparative phosphoproteomics reveals evolutionary and functional conservation of phosphorylation across eukaryotes
por: Boekhorst, Jos, et al.
Publicado: (2008)

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
por: Roller, Devin G., et al.
Publicado: (2015)

Elucidating Fibroblast Growth Factor–Induced Kinome Dynamics Using Targeted Mass Spectrometry and Dynamic Modeling
por: Veth, Tim S., et al.
Publicado: (2023)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Proteogenomic Features of the Highly Polymorphic Histidine-rich Glycoprotein Arose Late in Evolution
por: Zou, Yang, et al.
Publicado: (2023)

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
por: Kemper, Kristel, et al.
Publicado: (2016)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Quantifying Positional Isomers (QPI) by Top-Down Mass Spectrometry
por: Brunner, Andrea M., et al.
Publicado: (2021)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

Quantitative Map of Proteome Dynamics during Neuronal Differentiation
por: Frese, Christian K., et al.
Publicado: (2017)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Unravelling the Neospora caninum secretome through the secreted fraction (ESA) and quantification of the discharged tachyzoite using high-resolution mass spectrometry-based proteomics
por: Pollo-Oliveira, Letícia, et al.
Publicado: (2013)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Agents to treat BRAF-mutant lung cancer
por: Alvarez, Jean G Bustamante, et al.
Publicado: (2019)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Talin-KANK1 interaction controls the recruitment of cortical microtubule stabilizing complexes to focal adhesions
por: Bouchet, Benjamin P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3r9gegg21sbif0j9kqpbo9hkms